Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Proposes To Exempt Dozens Of Devices From 510(k) Requirements

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to exempt an array of class II and class I medical devices from premarket submission requirements because the devices are sufficiently well understood and do not present risks that require premarket notification review to assure their safety and effectiveness.

You may also be interested in...



Industry, FDA Agree On Draft User Fee Commitment Letter

Draft commitment and legislative language come one month after agreement “in principle” on MDUFA III reauthorization.

Canadian Generics Group Launches Cost-Saving Campaign

The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.

EU Packaging Regulation Presents Challenge And Opportunity For Consumer Health Industry

A proposed new European Union packaging regulation, which introduces environmental and labelling requirements and extended producer responsibility for medicines, medical devices and food supplements, could be challenging for the region's consumer health industry. But it could also be a spur to creativity, argues Chris Whitehouse, chairman and managing director of Whitehouse Communications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel